Liposomal doxorubicin in breast cancer. - Wikidata - awgldk - TriplyDB

Liposomal doxorubicin in breast cancer.

Liposomal doxorubicin in breast cancer.

http://www.wikidata.org/entity/Q37608442

about

Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer

P2860

Q36917747-97753FAA-4227-4B5B-8789-6FDFD1A84A29

P2860

Liposomal doxorubicin in breast cancer.

http://www.wikidata.org/entity/Q37608442

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2007

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Liposomal doxorubicin in breast cancer.

@en

Liposomal doxorubicin in breast cancer.

@nl

type

label

Liposomal doxorubicin in breast cancer.

@en

Liposomal doxorubicin in breast cancer.

@nl

prefLabel

Liposomal doxorubicin in breast cancer.

@en

Liposomal doxorubicin in breast cancer.

@nl

P1433

Q37608442-EE0408EA-E525-4E80-BAE2-DB6B3E6FCDFF

P1476

Q37608442-B33DC8CF-28AD-414B-BBEA-ABB7D86EAAD8

P2093

Q37608442-011186B7-16EA-4C19-B18F-B817D14F0096

Q37608442-1DFA29B4-9D5F-4C00-B028-06807B8986A5

Q37608442-7D11FFAA-B40A-4763-A5B5-5E0A8D56630D

Q37608442-8A32711D-DEFD-475B-8A9F-ED2B300E5CB3

P2860

Q37608442-0AEB8F8B-6A57-493C-B9BB-89D5393B0334

Q37608442-0E4EC39D-2A89-4848-A81D-0672ACA6D9E2

Q37608442-0F6FC847-6DB2-4CF0-8639-D1BF566C71D5

Q37608442-253592BB-BCBC-44EF-9F45-596F04CD4DEB

Q37608442-295B63FF-672B-4147-9A6D-B4531C2F72E0

Q37608442-2ACF7B53-6B57-4C0B-B1B2-7AA5ECA7C220

Q37608442-36E9772E-4A31-4E92-82D1-08ED457E2242

Q37608442-460A159C-8DEB-4E33-B763-2F67BA30294D

Q37608442-4AF14B7C-9217-43C1-ACDC-0F090CB20863

Q37608442-508B798E-1319-4065-B8CD-CA1609AB75E6

P304

Q37608442-9D443F8B-62F8-44B1-88D0-AC592EEA78A5

P31

Q37608442-803F04FB-72F6-4F86-AD54-31F50084C629

P356

Q37608442-C83B9C91-82DA-411E-909B-6E5A4413B9CD

P433

Q37608442-22F85DDA-3281-47E9-B7D9-53A6BC8FD9F5

P478

Q37608442-8A7E73E6-204C-45E9-B828-EAA2CD25FF7E

P577

Q37608442-16373BA3-ECB9-48A2-B678-7723DB658236

P698

Q37608442-8CF6729B-EAC7-4E75-83A5-1896551A0216

P356

17455057.3.5.557

P1433

P1476

Liposomal doxorubicin in breast cancer.

@en

P2093

A Mukherjee

http://www.w3.org/2001/XMLSchema#string

M Shehata

http://www.w3.org/2001/XMLSchema#string

R Sharma

http://www.w3.org/2001/XMLSchema#string

S Chan

http://www.w3.org/2001/XMLSchema#string

P2860

Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group

Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum.

Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer.

Phase I study of Caelyx (doxorubicin HCL, pegylated liposomal) in recurrent or metastatic head and neck cancer.

Phase I study of stealth liposomal doxorubicin in combination with gemcitabine in the treatment of patients with metastatic breast cancer.

The clinical utility of liposomal doxorubicin in recurrent ovarian cancer.

Phase II study of pegylated liposomal doxorubicin plus vinorelbine in breast cancer with previous anthracycline exposure.

A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin.

Phase I and pharmacokinetic trial of liposome-encapsulated doxorubicin.

Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials.

P304

557-569

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/17455057.3.5.557

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2007-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19804033

http://www.w3.org/2001/XMLSchema#string